目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 BIOBANKING MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024
2.2.1.1 Company revenue analysis (bottom-up approach)
2.2.1.2 MnM repository analysis
2.2.1.3 Primary interviews
2.2.1.4 Insights from primary sources
2.2.2 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE FORECAST
2.3.1 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
2.3.2 BIOBANKING MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
3.2.1 BIOBANKING EQUIPMENT MANUFACTURERS
3.2.2 BIOBANKING CONSUMABLE MANUFACTURERS
3.2.3 BIOBANKING SERVICE PROVIDERS

4 PREMIUM INSIGHTS
4.1 BIOBANKING MARKET OVERVIEW
4.2 NORTH AMERICA: BIOBANKING MARKET, BY OFFERING AND COUNTRY, 2024
4.3 BIOBANKING PRODUCTS MARKET SHARE, BY END USER, 2024
4.4 BIOBANKING SERVICES MARKET SHARE, BY END USER, 2024
4.5 BIOBANKING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing focus on precision medicine & population genomics programs
5.2.1.2 Expansion of cell & gene therapy pipeline
5.2.1.3 Adoption of energy-efficient ULT freezers
5.2.1.4 Integration of end-to-end automation & robotics for sample handling & storage
5.2.2 RESTRAINTS
5.2.2.1 High capital expenditure
5.2.2.2 Variability associated with sample quality
5.2.3 OPPORTUNITIES
5.2.3.1 Outsourcing of activities by SME biopharma companies to third-party specialists
5.2.3.2 Increasing focus on sustainability & green-lab solutions
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with long-term funding stability for public biobanks
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.3.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE OF BIOBANKING PRODUCTS, BY KEY PLAYER, 2024
5.4.2 INDICATIVE PRICING OF BIOBANKING SERVICES, BY SERVICE TYPE, 2024
5.4.3 INDICATIVE PRICING TREND FOR BIOBANKING MARKET, BY REGION, 2022-2024
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.6.1 ROLE IN ECOSYSTEM
5.6.2 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFT IN BIOBANKING MARKET
5.7 PATENT ANALYSIS
5.8 LIST OF KEY PATENTS
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Automated sample collection and processing technologies
5.9.1.2 Sample analysis technologies
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Data management & informatics
5.9.2.2 AI & ML in biobanking
5.10 KEY CONFERENCES & EVENTS, 2025-2026
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY FRAMEWORK
5.11.1.1 North America
5.11.1.2 Europe
5.11.1.3 Asia Pacific
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 TRADE ANALYSIS
5.12.1 IMPORT DATA FOR HS CODE 8418, 2020-2024
5.12.2 EXPORT DATA FOR HS CODE 8418, 2020-2024
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA FOR BIOBANKING PRODUCTS, BY END USER
5.14.3 KEY BUYING CRITERIA FOR BIOBANKING SERVICES, BY END USER
5.14.4 UNMET NEEDS & WHITE SPACES
5.15 INVESTMENT & FUNDING SCENARIO
5.15.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE, 2024
5.16 IMPACT OF AI/GEN AI ON BIOBANKING MARKET
5.16.1 INTRODUCTION
5.16.2 USE CASES
5.16.3 FUTURE OF AI IN BIOBANKING MARKET ECOSYSTEM
5.17 IMPACT OF 2025 US TARIFF ON BIOBANKING MARKET
5.17.1 INTRODUCTION
5.17.2 KEY TARIFF RATES
5.17.3 PRICE IMPACT ANALYSIS
5.17.4 KEY IMPACTS ON COUNTRIES/REGIONS
5.17.4.1 North America
5.17.4.1.1 US
5.17.4.2 Europe
5.17.4.3 Asia Pacific
5.17.5 IMPACT ON END-USE INDUSTRIES
5.17.5.1 Biobanks
5.17.5.2 CROs

6 BIOBANKING MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 EQUIPMENT
6.2.1.1 Freezers & refrigerators
6.2.1.1.1 Storage of blood, DNA, and serum to fuel market growth
6.2.1.2 Cryogenic storage systems
6.2.1.2.1 Rising demand for cell & gene therapies to fuel market
6.2.1.3 Alarm & monitoring systems
6.2.1.3.1 Regulatory demand for continuous monitoring to support market growth
6.2.1.4 Thawing equipment
6.2.1.4.1 Growing demand for CAR-T and mRNA therapies to fuel uptake
6.2.1.5 Temperature & humidity control systems
6.2.1.5.1 Critical role in maintaining sample integrity to aid adoption
6.2.1.6 Other equipment & accessories
6.2.2 CONSUMABLES
6.2.2.1 Surging sample volumes and recurring demand to drive market
6.3 SERVICES
6.3.1 OUTSOURCING OF SERVICES TO CROS TO DRIVE MARKET
6.4 SOFTWARE
6.4.1 GROWING FOCUS ON AUTOMATION TO PROPEL MARKET

7 BIOBANKING PRODUCTS MARKET FOR EQUIPMENT, BY OPERATION TYPE
7.1 INTRODUCTION
7.2 MANUAL OPERATIONS
7.2.1 LARGE EXISTING INSTALLED BASE AND NO REQUIREMENT FOR SPECIALIZED LABOR TO DRIVE MARKET
7.3 AUTOMATED OPERATIONS
7.3.1 INCREASING INNOVATION AND RISING TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET

8 BIOBANKING PRODUCTS MARKET, BY WORKFLOW
8.1 INTRODUCTION
8.2 SAMPLE COLLECTION & STORAGE
8.2.1 LARGE RESEARCH COHORTS AND SUSTAINABILITY MANDATES TO DRIVE MARKET
8.3 SAMPLE PROCESSING
8.3.1 AUTOMATION DEMAND AND COMPLIANCE RULES TO FUEL MARKET
8.4 SAMPLE ANALYSIS
8.4.1 HIGH DEMAND FOR ACTIONABLE DATA TO FUEL MARKET
8.5 TRANSPORT & LOGISTICS
8.5.1 TEMPERATURE-SENSITIVE REQUIREMENTS TO SUPPORT PRODUCTS UPTAKE

9 BIOBANKING PRODUCTS MARKET, BY SAMPLE TYPE
9.1 INTRODUCTION
9.2 BLOOD PRODUCTS
9.2.1 EASE OF COLLECTION AND ANALYTICAL VERSATILITY TO PROPEL MARKET
9.3 SOLID TISSUES & ORGANS
9.3.1 GROWTH IN SPATIAL OMICS TO FUEL MARKET
9.4 STEM CELLS & CELL LINES
9.4.1 ADOPTION OF REGENERATIVE MEDICINE TO BOOST DEMAND
9.5 BIOLOGICAL FLUIDS
9.5.1 UTILIZATION FOR DISEASE-MECHANISM STUDIES TO FUEL UPTAKE
9.6 NUCLEIC ACIDS
9.6.1 INTEGRATION OF MULTI-OMICS TO BOOST DEMAND
9.7 HUMAN WASTE PRODUCTS
9.7.1 APPLICATIONS ACROSS MICROBIOME RESEARCH TO FUEL UPTAKE

10 BIOBANKING PRODUCTS MARKET, BY END USER
10.1 INTRODUCTION
10.2 BIOBANKS
10.2.1 GROWING FOCUS ON LIFE SCIENCES & CLINICAL RESEARCH TO BOOST DEMAND
10.3 CROS
10.3.1 GROWING FOCUS ON BIOMARKER TRIALS AND OUTSOURCING OF SERVICES TO SUPPORT MARKET

11 BIOBANKING SERVICES MARKET, BY OWNERSHIP
11.1 INTRODUCTION
11.2 PRIVATE/COMMERCIAL BIOBANKS
11.2.1 TECHNOLOGICALLY ADVANCED INFRASTRUCTURE AND COMPLIANCE OFFERINGS TO PROPEL MARKET
11.3 ACADEMIC & RESEARCH INSTITUTION BIOBANKS
11.3.1 FAVORABLE FUNDING ACTIVITIES TO BOOST DEMAND
11.4 NATIONAL/REGIONAL AGENCIES
11.4.1 GOVERNMENT FOCUS ON ADVANCING HEALTHCARE RESEARCH INITIATIVES TO DRIVE MARKET
11.5 HYBRID/PPP MODELS
11.5.1 HIGH CREDIBILITY AND AGILITY TO SUPPORT MARKET GROWTH
11.6 OTHER OWNERSHIP MODELS

12 BIOBANKING MARKET, BY APPLICATION
12.1 INTRODUCTION
12.2 RESEARCH APPLICATIONS
12.2.1 LIFE SCIENCE RESEARCH
12.2.1.1 Increasing focus on genomics projects to fuel uptake
12.2.2 CLINICAL RESEARCH
12.2.2.1 Growing regulatory requirements and decentralized & hybrid trials to support market growth
12.3 THERAPEUTIC APPLICATIONS
12.3.1 GROWING DEMAND FOR CELL & GENE THERAPIES TO PROPEL MARKET
12.4 DIAGNOSTIC APPLICATIONS
12.4.1 REQUIREMENT OF DISEASE-SPECIFIC SAMPLES TO BOOST DEMAND
12.5 OTHER APPLICATIONS

13 BIOBANKING SERVICES MARKET, BY TYPE
13.1 INTRODUCTION
13.2 PHYSICAL BIOBANKING SERVICES
13.2.1 MEGA-COHORTS IN ONCOLOGY & POPULATION GENOMICS TO PROPEL MARKET
13.3 VIRTUAL BIOBANKING
13.3.1 EASE OF SPECIMEN ACCESS FOR END USERS TO DRIVE MARKET
13.4 OTHER SERVICES

14 BIOBANKING SERVICES MARKET, BY END USER
14.1 INTRODUCTION
14.2 PHARMA-BIOTECH COMPANIES & CROS
14.2.1 EXPANDING DRUG DISCOVERY & DEVELOPMENT PIPELINE TO PROPEL MARKET
14.3 ACADEMIC & RESEARCH INSTITUTES
14.3.1 ADVANCEMENTS IN RESEARCH AND FAVORABLE GRANTS TO BOOST DEMAND
14.4 HOSPITALS & DIAGNOSTIC LABORATORIES
14.4.1 USE OF SAMPLES FOR THERAPEUTIC & DIAGNOSTIC PURPOSES TO AID MARKET

15 BIOBANKING MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2 US
15.2.2.1 US to dominate North American biobanking market during forecast period
15.2.3 CANADA
15.2.3.1 Strong public investment with national research networks and collaborations to support disease-focused biobanking
15.3 EUROPE
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2 GERMANY
15.3.2.1 High government funding and focus on advanced clinical research to augment market growth
15.3.3 UK
15.3.3.1 Presence of large-scale, population-based advanced research infrastructure to propel market growth
15.3.4 FRANCE
15.3.4.1 Growing focus on quality standards, open science, and international collaboration to support market growth
15.3.5 ITALY
15.3.5.1 Improved healthcare standards to support biobanking studies in cancer, rare diseases, and personalized medicine healthcare
15.3.6 SPAIN
15.3.6.1 Adoption of international standards and advanced government-backed infrastructure to aid market growth
15.3.7 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2 CHINA
15.4.2.1 Increased research collaborations and advancements in biobank infrastructure to drive market
15.4.3 JAPAN
15.4.3.1 Strong genomic research output and focus on AI-driven polygenic risk scoring to boost predictive healthcare innovation
15.4.4 INDIA
15.4.4.1 National and disease-specific initiatives for advanced precision medicine and healthcare innovation to aid market growth
15.4.5 AUSTRALIA
15.4.5.1 Increasing national investments in disease-specific, microbiome, and wildlife biobanks to accelerate market growth
15.4.6 SOUTH KOREA
15.4.6.1 Increased quality standards and more international collaborations to support human and environmental biobanking
15.4.7 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2 BRAZIL
15.5.2.1 Genetic diversity and large-scale stem cell & genomic initiatives to propel market growth
15.5.3 MEXICO
15.5.3.1 Favorable initiatives for improving population health research and representation in global genomic databases to drive market
15.5.4 REST OF LATIN AMERICA
15.6 MIDDLE EAST
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
15.6.2 GCC COUNTRIES
15.6.2.1 Kingdom of Saudi Arabia (KSA)
15.6.2.1.1 Investments in automated equipment biobank infrastructure, ISO accreditation, and Vision 2030 to boost market growth
15.6.2.2 UAE
15.6.2.2.1 Investments in AI-driven robotic biobanking to fuel market growth
15.6.2.3 Rest of GCC countries
15.6.3 REST OF MIDDLE EAST
15.7 AFRICA
15.7.1 GROWING STANDARDIZATION EFFORTS, INTERNATIONAL ACCREDITATION, AND CAPACITY-BUILDING TO PROPEL MARKET GROWTH
15.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
16.3 REVENUE ANALYSIS, 2020-2024
16.3.1 REVENUE ANALYSIS FOR BIOBANKING PRODUCTS, 2020-2024
16.3.2 REVENUE ANALYSIS FOR BIOBANKING SERVICES & SOFTWARE, 2020-2024
16.4 MARKET SHARE ANALYSIS, 2024
16.4.1 MARKET SHARE ANALYSIS FOR BIOBANKING PRODUCTS, 2024
16.4.2 MARKET SHARE ANALYSIS FOR BIOBANKING SERVICES & SOFTWARE, 2024
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2024
16.5.5.1 Company footprint
16.5.5.2 Region footprint
16.5.5.3 Offering footprint
16.5.5.4 Sample type footprint
16.5.5.5 Workflow footprint
16.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
16.6.5.1 Detailed list of key startups/SMEs
16.6.5.2 Competitive benchmarking of startups/ SMEs
16.7 COMPANY VALUATION & FINANCIAL METRICS
16.7.1 COMPANY VALUATION & FINANCIAL METRICS FOR BIOBANKING PRODUCTS MARKET
16.7.1.1 Company valuation
16.7.1.2 Financial metrics
16.7.2 COMPANY VALUATION & FINANCIAL METRICS FOR BIOBANKING SERVICES & SOFTWARE MARKET
16.7.2.1 Company valuation
16.7.2.2 Financial metrics
16.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT/SERVICE/SOLUTION LAUNCHES
16.9.2 DEALS
16.9.3 EXPANSIONS

17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 THERMO FISHER SCIENTIFIC INC.
17.1.1.1 Business overview
17.1.1.2 Products/Services/Solutions offered
17.1.1.3 Recent developments
17.1.1.3.1 Product launches
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses & competitive threats
17.1.2 PHC HOLDINGS CORPORATION
17.1.2.1 Business overview
17.1.2.2 Products/Services/Solutions offered
17.1.2.3 Recent developments
17.1.2.3.1 Product launches
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses & competitive threats
17.1.3 BECTON, DICKINSON AND COMPANY (BD)
17.1.3.1 Business overview
17.1.3.2 Products/Services/Solutions offered
17.1.3.3 Recent developments
17.1.3.3.1 Product launches
17.1.3.4 MnM view
17.1.3.4.1 Key strengths
17.1.3.4.2 Strategic choices
17.1.3.4.3 Weaknesses & competitive threats
17.1.4 QIAGEN
17.1.4.1 Business overview
17.1.4.2 Products/Services/Solutions offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches
17.1.4.4 MnM view
17.1.4.4.1 Key strengths
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses & competitive threats
17.1.5 MERCK KGAA
17.1.5.1 Business overview
17.1.5.2 Products/Services/Solutions offered
17.1.5.3 Recent developments
17.1.5.3.1 Expansions
17.1.5.4 MnM view
17.1.5.4.1 Key strengths
17.1.5.4.2 Strategic choices
17.1.5.4.3 Weaknesses & competitive threats
17.1.6 AVANTOR, INC.
17.1.6.1 Business overview
17.1.6.2 Products/Services/Solutions offered
17.1.6.3 Recent developments
17.1.6.3.1 Deals
17.1.6.3.2 Expansions
17.1.7 CRYOPORT
17.1.7.1 Business overview
17.1.7.2 Products/Services/Solutions offered
17.1.7.3 Recent developments
17.1.7.3.1 Product launches
17.1.7.3.2 Deals
17.1.7.3.3 Expansions
17.1.8 TECAN TRADING AG
17.1.8.1 Business overview
17.1.8.2 Products/Services/Solutions offered
17.1.8.3 Recent developments
17.1.8.3.1 Product launches
17.1.9 AZENTA US INC.
17.1.9.1 Business overview
17.1.9.2 Products/Services/Solutions offered
17.1.9.3 Recent developments
17.1.9.3.1 Product launches
17.1.9.3.2 Deals
17.1.9.3.3 Expansions
17.1.10 GREINER AG
17.1.10.1 Business overview
17.1.10.2 Products/Services/Solutions offered
17.1.10.3 Recent developments
17.1.10.3.1 Product launches
17.1.10.3.2 Expansions
17.1.11 AGILENT TECHNOLOGIES, INC.
17.1.11.1 Business overview
17.1.11.2 Products/Services/Solutions offered
17.1.12 LABCORP
17.1.12.1 Business overview
17.1.12.2 Products/Services/Solutions offered
17.1.12.3 Recent developments
17.1.12.3.1 Deals
17.1.13 EUROFINS SCIENTIFIC
17.1.13.1 Business overview
17.1.13.2 Products/Services/Solutions offered
17.2 OTHER PLAYERS
17.2.1 HAIER BIOMEDICAL
17.2.2 HAMILTON COMPANY
17.2.3 AMSBIO
17.2.4 BAY BIOSCIENCES
17.2.5 BIOKRYO
17.2.6 SPT LABTECH LTD.
17.2.7 ASKION GMBH
17.2.8 CTIBIOTECH
17.2.9 CURELINE
17.2.10 FIRALIS MOLECULAR PRECISION
17.2.11 SOPACHEM
17.2.12 FROILABO
17.2.13 BIOIVT

18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS